Economic burden of atrial fibrillation: Implications for intervention

American Journal of Pharmacy Benefits

Volumn 4, Issue 2, 2012, Pages 58-65

  Reynolds, Matthew R ^a   Essebag, Vidal ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIARRHYTHMIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DABIGATRAN; DIGITALIS; DIGOXIN; DISOPYRAMIDE; DRONEDARONE; IRBESARTAN; PLACEBO; PROCAINAMIDE; QUINIDINE; SOTALOL; WARFARIN;

ADVERSE OUTCOME; AGING; ANTICOAGULANT THERAPY; BLEEDING; CARDIOVERSION; CATHETER ABLATION; CLINICAL PRACTICE; COMORBIDITY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG MEGADOSE; EMBOLISM; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART FAILURE; HOSPITALIZATION COST; HUMAN; INTERNATIONAL NORMALIZED RATIO; MEDICARE; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PATIENT MONITORING; PRACTICE GUIDELINE; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STROKE; SURVIVAL RATE; THROMBOEMBOLISM; UNITED STATES;

EID: 84859785660     PISSN: 19454481     EISSN: 21642494     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Bajpai A, Savelieva I, Camm AJ. Treatment of atrial fibrillation. Br Med Bull. 2008;88(1):75-94.
2. Bajpai A, Savelieva I, Camm AJ. Epidemiology and economic burden of atrial fibrillation. Touch Briefings. 2007;14-17. http://www.touchbriefings.com/pdf/2777/bajpai.pdf. Accessed February 10, 2012.
3. Boulanger L, Kim J, Friedman M, Hauch O, Foster T, Menzin J. Patterns of use of antithrombotic therapy and quality of anticoagulation among patients with nonvalvular atrial fibrillation in clinical practice. Int J Clin Pract. 2006;60(3):258-264.
4. Brüggenjürgen B, Rossnagel K, Roll S, et al. The impact of atrial fibrillation on the cost of stroke: the Berlin acute stroke study. Value Health. 2007;10(2): 137-143.
5. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009;104(11): 1534-1539.
6. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370-2375.
7. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence [published correction appears in Circulation. 2006;114(11):e498]. Circulation. 2006;114(2):119-125.
8. Caro JJ. An interview with J. Jaime Caro. Am J Manag Care. 2004;10(10) (suppl):S307-S311.
9. Krahn AD, Manfreda J, Tate RB, et al. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med. 1995;98(5):476-484.
10. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med. 2002;113(5):359-364.
11. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98(10):946-952.
12. Vidaillet H, Granada JF, Chyou PH, et al. A population-based study of mortality among patients with atrial fibrillation or flutter. Am J Med. 2002;113(5):365-370.
13. Chatap G, Giraud K, Vincent JP. Atrial fibrillation in the elderly: facts and management. Drugs Aging. 2002;19(11):819-846.
14. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983-988.
15. Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation: the Framingham Study. Stroke. 1996;27(10):1760-1764.
16. Coyne KS, Paramore C, Grandy S, Mercader M, Reynolds M, Zimetbaum P. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health. 2006;9(5):348-356.
17. Kim MH, Klingman D, Lin J, Pathak P, Battleman DS. Cost of hospital admission for antiarrhythmic drug initiation in atrial fibrillation. Ann Pharmacother. 2009;43(5):840-848.
18. Wattigney WA, Mensah GA, Croft JB. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation. 2003;108(6):711-716.
19. Reynolds MR, Essebag V, Zimetbaum P, Cohen DJ. Healthcare resource utilization and costs associated with recurrent episodes of atrial fibrillation: the FRACTAL registry. J Cardiovasc Electrophysiol. 2007;18(6):628-633.
20. Rohrbacker NJ, Kleinman NL, White SA, March JL, Reynolds MR. The burden of atrial fibrillation and other cardiac arrhythmias in an employed population: associated costs, absences, and objective productivity loss. J Occup Environ Med. 2010;52(4):383-391.
21. Ringborg A, Nieuwlaat R, Lindgren P, et al. Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation. Europace. 2008;10(4):403-411.
22. Wu EQ, Birnbaum HG, Mareva M, et al. Economic burden and co-morbidities of atrial fibrillation in a privately insured population. Curr Med Res Opin. 2005;21 (10):1693-1699.
23. Kim MH, Lin J, Hussein M, Battleman D. Incidence and temporal pattern of hospital readmissions for patients with atrial fibrillation. Curr Med Res Opin. 2009; 25(5):1215-1220.
24. Patel PP, Johnston SJ, Lin J, Schulman KL, Naccarelli GV. Cost burden of hospitalization and mortality in United States atrial fibrillation/flutter patients [abstract PO03-53]. Presented at: Heart Rhythm Meeting; May 13-16, 2009; Boston, MA.
25. Kim MH, Lin J, Hussein M, Kreilick C, Battleman D. Cost of atrial fibrillation in United States managed care organizations. Adv Ther. 2009;26(9):847-857.
26. Kim MH, Lin J, Hussein M, Battleman D. Incidence and economic burden of suspected adverse events and adverse event monitoring during AF therapy. Curr Med Res Opin. 2009;25(12):3037-3047.
27. Fuster V, Rydén LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol. 2011;57(11):e101-e198.
28. Lloyd-Jones D, Adams R, Carnethon M, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee [published correction appears in Circulation. 2011;124(16):e424]. Circulation. 2009;119(3):e21-e181.
29. Roger VL, Go AS, Lloyd-Jones DM, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2011 update: a report from the American Heart Association [published correction appears in Circulation. 2011;123(6):e240]. Circulation. 2011;123(4):459-463.
30. Khoo CW, Lip GY. Clinical outcomes of acute stroke patients with atrial fibrillation. Expert Rev Cardiovasc Ther. 2009;7(4):371-374.
31. Caro JJ. An economic model of stroke in atrial fibrillation: the cost of suboptimal oral anticoagulation. Am J Manag Care. 2004;10(14)(suppl):S451-S458.
32. Lee WC, Lamas GA, Balu S, Spalding J, Wang Q, Pashos CL. Direct treatment cost of atrial fibrillation in the elderly American population: a Medicare perspective. J Med Econ. 2008;11(2):281-298.
33. Dulli DA, Stanko H, Levine RL. Atrial fibrillation is associated with severe acute ischemic stroke. Neuroepidemiology. 2003;22(2):118-123.
34. Lamassa M, Di Carlo A, Pracucci G, et al. Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project). Stroke. 2001;32(2):392-398.
35. de Denus S, Sanoski CA, Carlsson J, Opolski G, Spinler SA. Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis. Arch Intern Med. 2005; 165(3):258-262.
36. Marshall DA, Levy AR, Vidaillet H, et al; AFFIRM and CORE Investigators. Costeffectiveness of rhythm versus rate control in atrial fibrillation. Ann Intern Med. 2004;141(9):653-661.
37. Pietrasik A, Kosior DA, Niewada M, Opolski G, Latek M, Kamiñski B. The cost comparison of rhythm and rate control strategies in persistent atrial fibrillation. Int J Cardiol. 2007;118(1):21-27.
38. Hagens VE, Vermeulen KM, TenVergert EM, et al; RACE study group. Rate control is more cost-effective than rhythm control for patients with persistent atrial fibrillation-results from the RAte Control versus Electrical cardioversion (RACE) study. Eur Heart J. 2004;25(17):1542-1549.
39. Botkin SB, Dhanekula LS, Olshansky B. Outpatient cardioversion of atrial arrhythmias: efficacy, safety, and costs. Am Heart J. 2003;145(2):233-238.
40. Agency for Healthcare Research and Quality. The Healthcare Cost and Utilization Project (HCUP). HCUPnet Web site. http://hcupnet.ahrq.gov/. Accessed June 2010.
41. Zimetbaum P, Reynolds MR, Ho KK, et al. Impact of a practice guideline for patients with atrial fibrillation on medical resource utilization and costs. Am J Cardiol. 2003;92(6):677-681.
42. Waldo AL, Becker RC, Tapson VF, Colgan KJ; NABOR Steering Committee. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol. 2005;46(9): 1729-1736.
43. Reynolds MR, Shah J, Essebag V, et al. Patterns and predictors of warfarin use in patients with new-onset atrial fibrillation from the FRACTAL Registry. Am J Cardiol. 2006;97(4):538-543.
44. ACTIVE Investigators; Connolly SJ, Pogue J, Hart RG, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009;360(20):2066-2078.
45. Food and Drug Administration. FDA approves Pradaxa to prevent stroke in people with atrial fibrillation. October 19, 2010. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm230241.htm. Accessed July 13, 2011.
46. Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation [published correction appears in N Engl J Med. 2010;363(19):1877]. N Engl J Med. 2009;361(12):1139-1151.
47. Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011;154(1):1-11.
48. Wann LS, Curtis AB, January CT, et al; ACCF/AHA Task Force Members. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines [published correction appears in Circulation. 2011;124(5):e173]. Circulation. 2011;123(1):104-123.
49. Multaq [package insert]. Bridgewater, NJ: sanofi-aventis US LLC; 2012.
50. Hohnloser SH, Crijns HJ, van Eickels M, et al; ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation [published corrections appear in N Engl J Med. 2011;364(15):1481 and N Engl J Med. 2009;360(23): 2487]. N Engl J Med. 2009;360(7):668-678.
51. Connolly SJ, Crijns HJ, Torp-Pedersen C, et al; ATHENA Investigators. Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. Circulation. 2009;120(13):1174-1180.
52. Kober L, Torp-Pedersen C, McMurray JJ, et al; Dronedarone Study Group. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358(25):2678-2687.
53. Naccarelli GV, Johnston SS, Lin J, Patel PP, Schulman KL. Cost burden of cardiovascular hospitalization and mortality in ATHENA-like patients with atrial fibrillation/atrial flutter in the United States. Clin Cardiol. 2010;33(5):270-279.
54. Nault I, Miyazaki S, Forclaz A, et al. Drugs vs. ablation for the treatment of atrial fibrillation: the evidence supporting catheter ablation. Eur Heart J. 2010; 31(9):1046-1054.
55. Jaïs P, Cauchemez B, Macle L, et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study [published correction appears in Circulation. 2009;120(10):e83]. Circulation. 2008;118(24):2498-2505.
56. Oral H, Pappone C, Chugh A, et al. Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med. 2006;354(9):934-941.
57. Pappone C, Augello G, Sala S, et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study. J Am Coll Cardiol. 2006;48(11):2340-2347.
58. Stabile G, Bertaglia E, Senatore G, et al. Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study). Eur Heart J. 2006;27(2):216-221.
59. Piccini JP, Lopes RD, Kong MH, Hasselblad V, Jackson K, Al-Khatib SM. Pulmonary vein isolation for the maintenance of sinus rhythm in patients with atrial fibrillation: a meta-analysis of randomized, controlled trials. Circ Arrhythm Electrophysiol. 2009;2(6):626-633.
60. Chan PS, Vijan S, Morady F, Oral H. Cost-effectiveness of radiofrequency catheter ablation for atrial fibrillation. J Am Coll Cardiol. 2006;47(12):2513-2520.
61. Khaykin Y, Morillo CA, Skanes AC, McCracken A, Humphries K, Kerr CR. Cost comparison of catheter ablation and medical therapy in atrial fibrillation. J Cardiovasc Electrophysiol. 2007;18(9):907-913.
62. Rodgers M, McKenna C, Palmer S, et al. Curative catheter ablation in atrial fibrillation and typical atrial flutter: systematic review and economic evaluation. Health Technol Assess. 2008;12(34):iii-iv, xi-xiii, 1-198.
63. Reynolds MR, Zimetbaum P, Josephson ME, Ellis E, Danilov T, Cohen DJ. Cost-effectiveness of radiofrequency catheter ablation compared with antiarrhythmic drug therapy for paroxysmal atrial fibrillation. Circ Arrhythm Electrophysiol. 2009;2(4):362-369.
64. Martin-Doyle W, Reynolds MR. Is AF ablation cost effective? J Atr Fibrillation. 2010;2(1):727-739.